Results 21 to 30 of about 15,404 (212)

Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

Scientific Reports, 2023
Sitagliptin has been suggested as a treatment option for older adults with type 2 diabetes (T2D). However, no randomized controlled trial has been performed to evaluate the efficacy and safety of sitagliptin treatment in older Japanese patients with T2D.
Mototsugu Nagao, Jun Sasaki, Hitoshi Sugihara, Kyoko Tanimura-Inagaki, Taro Harada, Ichiro Sakuma, Shinichi Oikawa, STREAM Study Investigators   +7 more
doaj   +1 more source

Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. [PDF]

PLoS ONE, 2015
BACKGROUND:The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain.
Szu-Heng Wang, Dong-Yi Chen, Yu-Sheng Lin, Chun-Tai Mao, Ming-Lung Tsai, Ming-Jer Hsieh, Chung-Chuan Chou, Ming-Shien Wen, Chun-Chieh Wang, I-Chang Hsieh, Kuo-Chun Hung, Tien-Hsing Chen   +11 more
doaj   +1 more source

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

Cardiovascular Diabetology, 2013
Objective To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes mellitus treated with sitagliptin or non-sitagliptin comparators.
Engel Samuel S, Golm Gregory T, Shapiro Deborah, Davies Michael J, Kaufman Keith D, Goldstein Barry J   +5 more
doaj   +1 more source

Pterostilbene vs sitagliptin

, 2023
Data share for the pterostilbene vs sitagliptin ...
Hayder Al-Aubaidy (14493926)
core   +2 more sources

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. [PDF]

PLoS ONE, 2012
BackgroundRecently, it has been suggested that enhancement of incretin effect improves cardiac function. We investigated the effect of a DPP-IV inhibitor, des-fluoro-sitagliptin, in reducing occurrence of restenosis in carotid artery in response to ...
Soo Lim, Sung Hee Choi, Hayley Shin, Bong Jun Cho, Ho Seon Park, Byung Yong Ahn, Seon Mee Kang, Ji Won Yoon, Hak Chul Jang, Young-Bum Kim, Kyong Soo Park   +10 more
doaj   +1 more source

Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin [PDF]

, 2023
A "honeymoon" phase is a transient period of type 1 diabetes (T1D) remission, characterized by a significant reduction in insulin requirements and good glycemic control due to a temporary restoration of pancreatic β-cell function.
Benido Silva, Vânia, Pereira, Maria Teresa   +1 more
core   +1 more source

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Frontiers in Medicine, 2022
The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg ...
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani   +13 more
doaj   +1 more source

Sitagliptin and Fractures in Type 2 Diabetes: A Nationwide Population-Based Propensity-Matching Study

Frontiers in Pharmacology, 2018
Background: Sitagliptin, a dipeptidyl peptidase-4 inhibitor possibly affects bone turnover. We conducted this cohort study to determine whether sitagliptin is associated with an increased risk of fracture.Methods: The sitagliptin cohort included 1,578 ...
Shih-Yi Lin, Shih-Yi Lin, Wu-Huei Hsu, Wu-Huei Hsu, Cheng-Chieh Lin, Cheng-Chieh Lin, Cheng-Li Lin, Cheng-Li Lin, Chun-Hao Tsai, Chun-Hao Tsai, Hung-Chieh Yeh, Chung-Y. Hsu, Chia-Hung Kao, Chia-Hung Kao, Chia-Hung Kao   +14 more
doaj   +1 more source

Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

International Journal of Endocrinology, 2014
New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to ...
Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy   +2 more
doaj   +1 more source

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia

Journal of Diabetes Investigation, 2019
Aims/Introduction To investigate the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus, with a focus on hypoglycemia.
Masahiro Fukuda, Kunihiro Doi, Masahiro Sugawara, Koichi Mochizuki   +3 more
doaj   +1 more source